title: [Effect of FUT-187, oral serine protease inhibitor, on inflammation in the gastric remnant].
abstract: Excessive enterogastric reflux following partial gastrectomy is believed to be responsible for the cause of inflammation in the gastric remnant. We examined the effect of FUT-187, a synthetic serine protease inhibitor, on symptoms and endoscopic findings in 33 patients who were diagnosed endoscopically as postgastrectomy gastritis. Patients took 50 mg FUT-187 orally after each meal and at bedtime for 8 weeks. Before treatment, 30 patients (91%) suffered from several symptoms including regurgitation and/or bitter taste in the mouth (49%), epigastric pain (42%) and nausea (36%). From endoscopic observation, erythema was detected in 32 patients, edema in 23 patients and erosion and/or ulcer in 9 patients. After treatment the global improvement rating for subjective symptoms was 76.7% (23/30) and the improvement of endoscopic findings was 63.6% (21/33). Diarrhea was observed in one patient but could be easily controlled by discontinuation of the drug. Our results suggest that FUT-187 can be a useful drug for the treatment of postgastrectomy gastritis with its efficacy and safety.
authors.affiliation: Dept. of Surgery II, Osaka University, Medical School.
authors.forename: H
authors.initials: H
authors.lastname: Shiozaki
authors.forename: M
authors.initials: M
authors.lastname: Inoue
authors.forename: S
authors.initials: S
authors.lastname: Tamura
authors.forename: T
authors.initials: T
authors.lastname: Iwanaga
authors.forename: M
authors.initials: M
authors.lastname: Imaoka
authors.forename: H
authors.initials: H
authors.lastname: Furukawa
authors.forename: M
authors.initials: M
authors.lastname: Hiratsuka
authors.forename: N
authors.initials: N
authors.lastname: Kikkawa
authors.forename: K
authors.initials: K
authors.lastname: Kobayashi
authors.forename: J
authors.initials: J
authors.lastname: Okamura
authors.forename: N
authors.initials: N
authors.lastname: Takada
authors.forename: Y
authors.initials: Y
authors.lastname: Ogawa
authors.forename: T
authors.initials: T
authors.lastname: Yamada
authors.forename: M
authors.initials: M
authors.lastname: Takami
authors.forename: T
authors.initials: T
authors.lastname: Takada
authors.forename: H
authors.initials: H
authors.lastname: Okuda
authors.forename: T
authors.initials: T
authors.lastname: Yano
authors.forename: T
authors.initials: T
authors.lastname: Satomi
authors.forename: T
authors.initials: T
authors.lastname: Kawasaki
authors.forename: S
authors.initials: S
authors.lastname: Oshima
authors.forename: K
authors.initials: K
authors.lastname: Yamasaki
authors.forename: H
authors.initials: H
authors.lastname: Imamoto
authors.forename: S
authors.initials: S
authors.lastname: Noguchi
authors.forename: N
authors.initials: N
authors.lastname: Fujimoto
authors.forename: T
authors.initials: T
authors.lastname: Mori
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D005743:Gastrectomy / Q000009:adverse effects*; D018530:Gastric Stump; D005756:Gastritis / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy*; D011480:Protease Inhibitors / Q000627:therapeutic use*
chemical_list: D007093:Imidazoles; D011480:Protease Inhibitors; C058875:sepimostate mesilate